$APTO
Aptose Biosciences Inc.

2022 Q1 Form 10-Q Financial Statement

#000117184322003463 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.089M $7.990M
YoY Change -48.82% 36.12%
% of Gross Profit
Research & Development $7.393M $8.228M
YoY Change -10.15% 38.66%
% of Gross Profit
Depreciation & Amortization $32.00K $35.00K
YoY Change -8.57% -14.63%
% of Gross Profit
Operating Expenses $11.50M $16.25M
YoY Change -29.24% 37.33%
Operating Profit
YoY Change
Interest Expense $19.00K $30.00K
YoY Change -36.67% -90.32%
% of Operating Profit
Other Income/Expense, Net $19.00K $25.00K
YoY Change -24.0% -91.88%
Pretax Income -$11.48M -$16.23M
YoY Change -29.26% 40.76%
Income Tax
% Of Pretax Income
Net Earnings -$11.48M -$16.23M
YoY Change -29.25% 40.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.18
Diluted Earnings Per Share -$124.5K -$182.6K
COMMON SHARES
Basic Shares Outstanding 92.23M 88.89M
Diluted Shares Outstanding 92.23M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.51M $112.1M
YoY Change -37.99% 24.56%
Cash & Equivalents $36.99M $87.08M
Short-Term Investments $32.52M $25.00M
Other Short-Term Assets $101.0K $116.0K
YoY Change -12.93% -0.85%
Inventory
Prepaid Expenses $2.262M $1.946M
Receivables
Other Receivables
Total Short-Term Assets $71.87M $114.1M
YoY Change -37.03% 25.45%
LONG-TERM ASSETS
Property, Plant & Equipment $287.0K $243.0K
YoY Change 18.11% -21.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $729.0K $1.051M
YoY Change -30.64% -33.1%
TOTAL ASSETS
Total Short-Term Assets $71.87M $114.1M
Total Long-Term Assets $729.0K $1.051M
Total Assets $72.60M $115.2M
YoY Change -36.97% 24.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.144M $1.608M
YoY Change -28.86% -20.28%
Accrued Expenses $5.646M $3.231M
YoY Change 74.74% 71.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.309M $5.369M
YoY Change 36.13% 21.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.00K $400.0K
YoY Change -97.5% -55.56%
Total Long-Term Liabilities $10.00K $400.0K
YoY Change -97.5% -55.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.309M $5.369M
Total Long-Term Liabilities $10.00K $400.0K
Total Liabilities $7.319M $5.789M
YoY Change 26.43% 8.82%
SHAREHOLDERS EQUITY
Retained Earnings -$434.0M -$373.4M
YoY Change 16.23% 19.12%
Common Stock $437.4M $429.7M
YoY Change 1.81% 17.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.28M $109.4M
YoY Change
Total Liabilities & Shareholders Equity $72.60M $115.2M
YoY Change -36.97% 24.46%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$11.48M -$16.23M
YoY Change -29.25% 40.79%
Depreciation, Depletion And Amortization $32.00K $35.00K
YoY Change -8.57% -14.63%
Cash From Operating Activities -$9.645M -$10.38M
YoY Change -7.05% 27.93%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $17.00K
YoY Change -100.0% 6.25%
Acquisitions
YoY Change
Other Investing Activities $7.505M -$20.00M
YoY Change -137.53% 61.16%
Cash From Investing Activities $7.505M -$20.01M
YoY Change -137.5% 61.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $15.00K $75.00K
YoY Change -80.0% -82.8%
NET CHANGE
Cash From Operating Activities -$9.645M -$10.38M
Cash From Investing Activities $7.505M -$20.01M
Cash From Financing Activities $15.00K $75.00K
Net Change In Cash -$2.123M -$30.31M
YoY Change -93.0% 50.89%
FREE CASH FLOW
Cash From Operating Activities -$9.645M -$10.38M
Capital Expenditures $0.00 $17.00K
Free Cash Flow -$9.645M -$10.39M
YoY Change -7.2% 27.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
459000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7309000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8174000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
115000 USD
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
92229189
CY2022Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
442000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
465000 USD
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
729000 USD
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
788000 USD
CY2022Q1 us-gaap Assets
Assets
72603000 USD
CY2022Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92229189
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92229189
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92215024
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92215024
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q1 apto Employee Stock Purchase Plan Maximum Payroll Deduction Percent
EmployeeStockPurchasePlanMaximumPayrollDeductionPercent
0.15 pure
CY2022Q1 apto Employee Stock Purchase Plan Stock Purchase Price Percent
EmployeeStockPurchasePlanStockPurchasePricePercent
0.85 pure
CY2021 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36991000 USD
CY2021Q4 us-gaap Assets
Assets
82525000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1144000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1699000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5646000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6016000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
519000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39114000 USD
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
32520000 USD
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
40014000 USD
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2262000 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2476000 USD
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
101000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
133000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
71874000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
81737000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
287000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
323000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
7319000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
8289000 USD
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
437412000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
437386000 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66176000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63673000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4316000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4316000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-433988000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8024000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-422507000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7393000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8228000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4107000 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11500000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
16252000 USD
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
22000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11481000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16227000 USD
CY2022Q1 apto Earnings Per Share Basic And Diluted Total
EarningsPerShareBasicAndDilutedTotal
-0.12
CY2021Q1 apto Earnings Per Share Basic And Diluted Total
EarningsPerShareBasicAndDilutedTotal
-0.18
CY2022Q1 apto Weighted Average Number Of Shares Outstanding Basic And Diluted Total
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal
92226000
CY2021Q1 apto Weighted Average Number Of Shares Outstanding Basic And Diluted Total
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal
88884000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
74236000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11481000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
118915000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6643000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16227000 USD
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
143000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
109406000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
137000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11481000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-555000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-563000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16227000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-370000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2514000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-871000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9645000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10376000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6643000 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
35000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
114000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
117000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75000 USD
CY2022Q1 apto Interest On Lease Liabilities
InterestOnLeaseLiabilities
7000 USD
CY2021Q1 apto Interest On Lease Liabilities
InterestOnLeaseLiabilities
13000 USD
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000 USD
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0 USD
CY2022Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-7505000 USD
CY2021Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
19995000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7505000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20012000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000 USD
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2123000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30310000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2514000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39114000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
117393000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36991000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87083000 USD
CY2022Q1 apto Interest Accrued On Investments
InterestAccruedOnInvestments
11000 USD
CY2021Q1 apto Interest Accrued On Investments
InterestAccruedOnInvestments
4000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-214000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-608000 USD
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-32000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
65284000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
74236000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72603000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82525000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-3000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-2000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
65284000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-13000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3000 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:36pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant accounting policies, estimates and judgments:</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 54pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022, </em>there have been <em style="font: inherit;">no</em> changes to our significant accounting policies as described in our Annual Report on Form <em style="font: inherit;">10</em>-K for the fiscal year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The preparation of the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The impacts of such estimates are pervasive throughout the condensed consolidated interim financial statements and <em style="font: inherit;"> may </em>require accounting adjustments based on future occurrences.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:36pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(e)</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Concentration of risk:</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The Company is subject to credit risk from the Company’s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of <em style="font: inherit;">R1‑low</em> or A‑low investments and the Company invests only in highly rated corporations and treasury bills, which are capable of prompt liquidation.</p>
CY2022Q1 us-gaap Cash
Cash
279000 USD
CY2021Q4 us-gaap Cash
Cash
294000 USD
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
36712000 USD
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
38820000 USD
CY2022Q1 apto Prepaid Research And Development
PrepaidResearchAndDevelopment
956000 USD
CY2021Q4 apto Prepaid Research And Development
PrepaidResearchAndDevelopment
632000 USD
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1306000 USD
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1844000 USD
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2262000 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2476000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
40014000 USD
CY2021Q4 apto Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
1860000 USD
CY2020Q4 apto Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
1848000 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
91000 USD
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12000 USD
CY2022Q1 apto Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
1951000 USD
CY2021Q4 apto Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
1860000 USD
CY2022Q1 apto Amortization Of Rightof Use Assets
AmortizationOfRightofUseAssets
1509000 USD
CY2021Q4 apto Amortization Of Rightof Use Assets
AmortizationOfRightofUseAssets
1395000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
442000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
465000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
32520000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
0 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
32520000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
40014000 USD
CY2021Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
0 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
403000 USD
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
69232000 USD
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
78834000 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1044000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2152000 USD
CY2022Q1 apto Research And Development Liabilities Current
ResearchAndDevelopmentLiabilitiesCurrent
4263000 USD
CY2021Q4 apto Research And Development Liabilities Current
ResearchAndDevelopmentLiabilitiesCurrent
3520000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
339000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
344000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5646000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6016000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
140000 USD
CY2022Q1 apto Lessee Operating Lease Liability To Be Paid After Year One
LesseeOperatingLeaseLiabilityToBePaidAfterYearOne
0 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
543000 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0514 pure
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0537 pure
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
519000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
459000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
115000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
529000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
574000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7887000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.34
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11481000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16227000 USD
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.08
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
349000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.77
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18619000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.97
CY2022Q1 apto Weighted Average Number Of Shares Outstanding Basic And Diluted Total
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal
92226000
CY2021Q1 apto Weighted Average Number Of Shares Outstanding Basic And Diluted Total
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal
88884000
CY2022Q1 apto Earnings Per Share Basic And Diluted Total
EarningsPerShareBasicAndDilutedTotal
-0.12
CY2021Q1 apto Earnings Per Share Basic And Diluted Total
EarningsPerShareBasicAndDilutedTotal
-0.18
CY2022Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15112000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
121000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
130000 USD
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
143000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
137000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.61
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3870000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10736000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.68
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
17344000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.03
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11942000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.97
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2962000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.47
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
39000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.97
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
703000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.67
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14162000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.85
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.59
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M12D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13220000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.83
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y11M26D
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6990000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.833 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.807 pure
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.89
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3870000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2962000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2514000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6643000 USD

Files In Submission

Name View Source Status
0001171843-22-003463-index-headers.html Edgar Link pending
0001171843-22-003463-index.html Edgar Link pending
0001171843-22-003463.txt Edgar Link pending
0001171843-22-003463-xbrl.zip Edgar Link pending
apto-20220331.xsd Edgar Link pending
apto-20220331_cal.xml Edgar Link unprocessable
apto-20220331_def.xml Edgar Link unprocessable
apto-20220331_lab.xml Edgar Link unprocessable
apto-20220331_pre.xml Edgar Link unprocessable
apto20220331_10q.htm Edgar Link pending
apto20220331_10q_htm.xml Edgar Link completed
ex_371593.htm Edgar Link pending
ex_371594.htm Edgar Link pending
ex_371595.htm Edgar Link pending
ex_371596.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
logo.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending